Jin‐Ku Lee

ORCID: 0000-0003-0263-3234
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cancer Cells and Metastasis
  • Glioma Diagnosis and Treatment
  • Cytokine Signaling Pathways and Interactions
  • Cancer Genomics and Diagnostics
  • Cancer, Hypoxia, and Metabolism
  • Glycosylation and Glycoproteins Research
  • Immune Cell Function and Interaction
  • HER2/EGFR in Cancer Research
  • PARP inhibition in cancer therapy
  • Proteoglycans and glycosaminoglycans research
  • Microtubule and mitosis dynamics
  • Liver physiology and pathology
  • melanin and skin pigmentation
  • Monoclonal and Polyclonal Antibodies Research
  • Bioactive natural compounds
  • RNA Research and Splicing
  • Medicinal Plant Pharmacodynamics Research
  • Ovarian cancer diagnosis and treatment
  • Estrogen and related hormone effects
  • PI3K/AKT/mTOR signaling in cancer
  • Integrated Circuits and Semiconductor Failure Analysis
  • Peroxisome Proliferator-Activated Receptors
  • Cancer, Stress, Anesthesia, and Immune Response
  • NF-κB Signaling Pathways
  • Neurogenesis and neuroplasticity mechanisms

Seoul National University
2010-2024

Seoul National University Hospital
2022-2024

Ajou University
2019-2020

Samsung Medical Center
2014-2019

Sungkyunkwan University
2013-2017

Samsung (South Korea)
2014-2015

Institute of Cell Biology and Neurobiology
2015

Cleveland Clinic Lerner College of Medicine
2015

New Generation University College
2012

Kyung Hee University
2012

Abstract Introduction: Protein kinase CK2 is implicated in cellular proliferation and transformation. However, the clinical biological significances of have not been elucidated acute myeloid leukemia (AML). Experimental Design: We evaluated catalytic subunit (CK2α) expression cell lines primary leukemic blasts obtained from AML patients. Results: In this study, CK2α was elevated a substantial proportion AML. patients with normal karyotype, disease-free survival overall rates were...

10.1158/1078-0432.ccr-06-1602 article EN Clinical Cancer Research 2007-02-01

Clinical benefits from standard therapies against glioblastoma (GBM) are limited in part due to intrinsic radio- and chemoresistance of GBM inefficient targeting stem-like cells (GSCs). Novel therapeutic approaches that overcome treatment resistance diminish properties needed. We determined the expression levels ubiquitination-specific proteases (USPs) by transcriptome analysis found USP1 is highly expressed GBM. Using patient GBM-derived primary tumor cells, we inhibited shRNA-mediated...

10.1093/neuonc/nov091 article EN Neuro-Oncology 2015-06-01

Background Intestinal epithelium is essential for maintaining normal intestinal homeostasis; its breakdown leads to chronic inflammatory pathologies, such as bowel diseases (IBDs). Although high concentrations of S100A9 protein and interleukin-6 (IL-6) are found in patients with IBD, the expression mechanism colonic epithelial cells (CECs) remains elusive. We investigated role IL-6 CECs using a colitis model. Methods expression, signal transducer activator transcription 3 (STAT3)...

10.1371/journal.pone.0038801 article EN cc-by PLoS ONE 2012-09-04

The acquisition of tamoxifen resistance is a major therapeutic problem in breast cancer. We developed tamoxifen-resistant MCF-7 (TRM-7) cell line to elucidate the molecular mechanisms and factors associated with such resistance. showed that phosphorylation STAT3 at tyrosine 705 (Y705) RANTES expression are increased response human cancer cells. On basis these results, we hypothesize upregulated may be correlated development drug Here, contribute maintenance constitutively retained via...

10.1158/1541-7786.mcr-12-0217 article EN Molecular Cancer Research 2012-10-17

Chimeric antigen receptor (CAR)-engineered natural killer (NK) cells are a promising immunotherapy for solid cancers; however, their effectiveness against pancreatic cancer is limited by the immunosuppressive tumor microenvironment. In particular, low NK cell infiltration poses major obstacle that reduces cytotoxicity. The current study aimed to enhance tumor-homing capacity of CAR-NK targeting chemokine-chemokine axis between and cells. To this end, data from chemokine array Cancer Genome...

10.1016/j.omton.2024.200777 article EN cc-by-nc-nd Deleted Journal 2024-02-19

Glioblastoma multiforme (GBM) is the most common and lethal primary brain tumor, with tragically little therapeutic progress over last 30 years. Surgery provides a modest benefit, GBM cells are resistant to radiation chemotherapy. Despite significant development of molecularly targeting strategies, clinical outcome patients remains dismal. The challenges inherent in developing effective treatments have become increasingly clear, include resistance standard treatments, blood-brain barrier,...

10.3892/ol.2016.4074 article EN Oncology Letters 2016-01-07

Abstract Glioblastoma (GBM) is the most lethal primary brain tumor with few treatment options. The survival of glioma-initiating cells (GICs) one major factors contributing to failure. GICs frequently produce and respond their own growth that support cell proliferation survival. In this study, we aimed identify critical autocrine mediating GIC evaluate anti-GBM effect antagonizing these factors. Proteomic analysis was performed using conditioned media from two different patient-derived GBM...

10.1038/s12276-019-0351-y article EN cc-by Experimental & Molecular Medicine 2019-12-01

Recent studies indicate that signaling molecules traditionally associated with central nervous system function play critical roles in cancer. Dopamine receptor is implicated various cancers including glioblastoma (GBM) and it a recognized therapeutic target, as evidenced by recent clinical trials selective dopamine D2 (DRD2) inhibitor ONC201. Understanding the molecular mechanism(s) of will be for development potent options. Using human GBM patient-derived tumors treated agonists...

10.1016/j.neo.2023.100894 article EN cc-by-nc-nd Neoplasia 2023-03-25

Glioblastoma (GBM) is the most malignant brain tumor with profound genomic alterations. Tumor suppressor genes regulate multiple signaling networks that restrict cellular proliferation and present barriers to transformation. While bona fide suppressors such as PTEN TP53 often undergo inactivation due mutations, there are several for which deletion primary route progression. To functionally identify putative in GBM, we employed vivo RNAi screening using patient-derived xenograft models. Here,...

10.1084/jem.20172170 article EN cc-by The Journal of Experimental Medicine 2019-03-21

Abstract Background Homologous recombination deficiency (HRD) stands as a clinical indicator for discerning responsive outcomes to platinum-based chemotherapy and poly ADP-ribose polymerase (PARP) inhibitors. One of the conventional approaches HRD prognostication has generally centered on identifying deleterious mutations within BRCA1/2 genes, along with quantifying genomic scars, such Genomic Instability Score (GIS) estimation scarHRD. However, scarHRD method limitations in scenarios...

10.1186/s12859-024-05854-y article EN cc-by BMC Bioinformatics 2024-07-12

Recently, statins have been shown to anti-inflammatory effects on lung inflammatory diseases. However, the mechanisms of action simvastatin in viral pneumonia yet be elucidated, although infection remains a considerable health threat. In this study, we hypothesised that inhibits polyinosinic-polycytidylic acid (poly I:C)-induced airway inflammation, such as RANTES (regulated activation, normal T-cell expressed and secreted) expression cell recruitment. bronchial cells, effect poly...

10.1183/09031936.00050612 article EN European Respiratory Journal 2012-07-26

Summary The naive T ‐cell pool in peripheral lymphoid tissues is fairly stable terms of number, diversity and functional capabilities spite the absence prominent stimuli. This stability attributed to continuous tuning composition by various homeostatic signals. Despite extensive research into link between signal transducer activator transcription 3 ( S tat3) survival, little known about how tat3 regulates homeostasis maintaining required population organs. We assessed whether elimination...

10.1111/imm.12133 article EN Immunology 2013-06-08

Abstract Axitinib, small molecule tyrosine kinase inhibitor, demonstrates anti-cancer activity for various solid tumors. We investigated effect of axitinib in epithelial ovarian cancer (EOC). treated EOC cells (A2780, HeyA8, RMG1, and HeyA8-MDR) with to evaluate its effects on cell viabilty, apoptosis migration. Western blots were performed assess VEGFR2, ERK, AKT levels, ELISA FACS according treatment. In addition, vivo experiments xenografts using A2780, HeyA8-MDR lines performed. repeated...

10.1038/s41598-020-61871-w article EN cc-by Scientific Reports 2020-03-17
Coming Soon ...